Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.
暂无分享,去创建一个
S. Digumarthy | A. Iafrate | C. Channick | J. Baselga | M. Mino‐Kenudson | L. Sequist | J. Engelman | N. Choi | B. A. Waltman | D. Dias-Santagata | P. Fidias | A. Shaw | R. Heist | J. Temel | J. Wain | T. Lynch | D. Mathisen | L. Ellisen | A. Muzikansky | H. Willers | I. Lennes | J. Gainor | J. Baselga | R. Rosovsky | D. Borger | H. Gaissert | C. Wright | L V Sequist | R S Heist | A T Shaw | P Fidias | R Rosovsky | J S Temel | I T Lennes | S Digumarthy | B A Waltman | E Bast | S Tammireddy | L Morrissey | A Muzikansky | S B Goldberg | J Gainor | C L Channick | J C Wain | H Gaissert | D M Donahue | A Muniappan | C Wright | H Willers | D J Mathisen | N C Choi | J Baselga | T J Lynch | L W Ellisen | M Mino-Kenudson | M Lanuti | D R Borger | A J Iafrate | J A Engelman | D Dias-Santagata | M. Lanuti | A. Muniappan | D. Donahue | H. Gaissert | S. Goldberg | E. Bast | S. Tammireddy | L. Morrissey | T. Lynch | Swathi Tammireddy | C. Wright | C. Wright
[1] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[2] J. Minna,et al. Genetic alteration of the β-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion , 2001, Oncogene.
[3] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[4] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[5] R. Ramlau,et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Toshihide Tsuda,et al. The TP53 gene, tobacco exposure, and lung cancer , 2003, Human mutation.
[7] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[8] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[9] Y. Miyagi,et al. Aberrant Nuclear/Cytoplasmic Localization and Gene Mutation of β-Catenin in Classic Pulmonary Blastoma: β-Catenin Immunostaining Is Useful for Distinguishing Between Classic Pulmonary Blastoma and a Blastomatoid Variant of Carcinosarcoma , 2004, The American journal of surgical pathology.
[10] M. Stratton,et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.
[11] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[12] R. Wilson,et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] N. Hanna,et al. EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .
[14] H. Sugimura,et al. PIK3CA mutation and amplification in human lung cancer , 2007, Pathology international.
[15] Johan Vansteenkiste,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. R. Jones. Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer , 2008 .
[17] J. Subramanian,et al. Molecular genetics of lung cancer in people who have never smoked. , 2008, The Lancet. Oncology.
[18] M. Ladanyi,et al. Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma , 2008, Clinical Cancer Research.
[19] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[20] W. Lam,et al. PIK3CA mutations and copy number gains in human lung cancers. , 2008, Cancer research.
[21] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[23] M. Ladanyi,et al. Integration of Molecular Profiling into the Lung Cancer Clinic , 2009, Clinical Cancer Research.
[24] W. Pao,et al. KRAS mutations in non-small cell lung cancer. , 2009, Proceedings of the American Thoracic Society.
[25] J. Uhm. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .
[26] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[27] H. Ji,et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[29] David N Louis,et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine , 2010, EMBO molecular medicine.
[30] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[31] M. Socinski,et al. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] L. Tanoue,et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .
[33] M. Ladanyi,et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[35] Clinical, pathologic, and molecular characteristics of patients with non-small cell lung cancer harboring mutations in PIK3CA. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] L. Tanoue. Use of Epidermal Growth Factor Receptor/Kirsten Rat Sarcoma 2 Viral Oncogene Homolog Mutation Testing to Define Clonal Relationships Among Multiple Lung Adenocarcinomas: Comparison With Clinical Guidelines , 2011 .
[37] L. Tanoue. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .
[38] N. Girard,et al. New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.
[39] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[40] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[41] L. Tanoue,et al. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .